Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer

Advaxis Inc. reported that 38.5% of advanced cervical cancer patients – a group that normally survives for four to seven months on average – survived for at least 12 months after treatment with the company's immunotherapy axalimogene filolisbac (ADXS-HPV) in the first stage of a 67-patient, investigator-initiated, two-stage Phase II clinical trial.